Gossamer Bio (NASDAQ:GOSS) Stock Rating Reaffirmed as “Buy” by Chardan Capital

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reissued by Chardan Capital in a research note issued to investors on Monday, Benzinga reports.

A number of other research firms also recently weighed in on GOSS. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research report on Tuesday, July 28th. Finally, HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $256.00.

Gossamer Bio Trading Down 2.1%

Shares of GOSS stock traded down $0.20 during trading hours on Monday, hitting $9.40. The company’s stock had a trading volume of 48,967 shares, compared to its average volume of 240,174. The business has a fifty day moving average of $11.48 and a 200-day moving average of $16.16. The stock has a market cap of $57.45 million, a price-to-earnings ratio of -0.17 and a beta of 2.21. Gossamer Bio has a twelve month low of $8.29 and a twelve month high of $309.60.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio in the 2nd quarter worth about $2,467,000. Kalehua Capital Management LLC bought a new stake in shares of Gossamer Bio in the 1st quarter worth about $3,363,000. ARCH Venture Management LLC bought a new stake in Gossamer Bio during the 2nd quarter worth about $1,326,004. BlackRock Inc. bought a new stake in Gossamer Bio during the 2nd quarter worth about $1,262,000. Finally, Corient Private Wealth LP grew its holdings in Gossamer Bio by 41.3% during the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after acquiring an additional 1,647,315 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.